Abstract:Covering 2010–April 2024 There have been tremendous new discoveries and developments since 2010 in anticancer research based on marine cyanobacteria. Marine cyanobacteria are prolific sources of anticancer natural products, including the tubulin agents dolastatins 10 and 15 which were originally isolated from a mollusk that feeds on cyanobacteria. Decades of research have culminated in the approval of six antibody-drug conjugates (ADCs) and many ongoing clinical trials. Antibody conjugation has been enabling for several natural products, particularly cyanobacterial cytotoxins. Targeting tubulin dynamics has been a major strategy, leading to the discovery of the gatorbulin scaffold, acting on a new pharmacological site. Cyanobacterial compounds with different mechanisms of action (MOA), targeting novel or validated targets in a range of organelles, also show promise as anticancer agents. Important advances include the development of compounds with novel MOA, including apratoxin and coibamide A analogues, modulating cotranslational translocation at the level of Sec61 in the endoplasmic reticulum, largazole and santacruzamate A targeting class I histone deacetylases, and proteasome inhibitors based on carmaphycins, resembling the approved drug carfilzomib. The pipeline extends with SERCA inhibitors, mitochondrial cytotoxins and membrane-targeting agents, which have not yet advanced clinically since the biology is less understood and selectivity concerns remain to be addressed. In addition, efforts have also focused on the identification of chemosensitizing and antimetastatic agents. The review covers the state of current knowledge of marine cyanobacteria as anticancer agents with a focus on the mechanism, target identification and potential for drug development. We highlight the importance of solving the supply problem through chemical synthesis as well as illuminating the biological activity and in-depth mechanistic studies to increase the value of cyanobacterial natural products to catalyze their development.

40 Years of Duocarmycins: A Graphical Structure/Function Review of Their Chemical Evolution, from SAR to Prodrugs and ADCs

A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

An Insight into the Medicinal Chemistry Perspective of Macrocyclic Derivatives with Antitumor Activity: A Systematic Review

Recent Advances In The Synthesis Of Lamellarins As Anticancer Alkaloids

Dynemicin A Derivatives as Potential Cancer Chemotherapeutics by Mutasynthesis

Molecules Containing Cyclobutyl Fragments as Therapeutic Tools: A Review on Cyclobutyl Drugs

Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents

Acridine and its derivatives: a patent review (2009 - 2013).

Progress in the discovery and development of anticancer agents from marine cyanobacteria

Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships

An Overview of Acridine Analogs: Pharmacological Significance and Recent Developments

Design, synthesis, molecular modeling and evaluation of 2,4-diaminopyrimidine analogues as promising colorectal cancer drugs

Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals

A decade's overview of 2‐aminothiophenes and their fused analogs as promising anticancer agents

Part I. Synthesis of macrocyclic arms and highly sequence selective receptors. Part II. Design and construction of a resin -bound reverse peptide library and studies towards understanding vancomycin's binding property

Synthesis of chamaecypanone C analogues from in situ-generated cyclopentadienones and their biological evaluation.

Antibody–Drug Conjugates—Evolution and Perspectives

Insight Into Factors Governing Formation, Synthesis and Stereochemical Configuration of DNA Adducts formed by Mitomycins

Advances in daptomycin biosynthesis

An updates: Oxidative aromatization of THβC to β-carbolines and their application for the β-carboline alkaloids synthesis